Anti-ara h 2 antibodies and uses thereof

A combination of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure, wherein the combination comprises three or more anti-Ara h 2 antibodies that bind the following Ara h 2 epitope bins:

• (a) a first epitope bin comprising epitopes of one or more of anti-Ara h 2 antibodies P34, T1, T3, P33, P17, P21, P3, P13, P10, P11, P14, P19, P28, P30, P39, U1, 13FU1P1A4, 13FU1P1B4, 14FU2P1A11, 15FU1P1A3, 13FU1P2B12, 11FUP1A2, 18FU1P1A7, 23FUP1A8, 23FUP1B8, 23FUP1C4, 23FUP1D6, 23FUP1D12, 24BU7P1A10, 24BU7P1B6, 24BU7P1D1, 24BU7P1C10, 24BU7P1D9, 24BU7P1C2, 105BU7P1A11, 105BU7P1C3, 105BU7P1D7, 105BU7P1 D12, and 33BU7P1 D11, wherein P34 comprises the following complementarity determining regions (CDRs):
• a CDR-H1 comprising the amino acid sequence of GFTFDDYT (SEQ ID NO:341), a CDR-H2 comprising the amino acid sequence of IRWDGSRT (SEQ ID NO:342), a CDR-H3 comprising the amino acid sequence of VKDGGLRYFDS (SEQ ID NO:343), a CDR-L1 comprising the amino acid sequence of QSLLHSNGIHY (SEQ ID NO:344), a CDR-L2 comprising the amino acid sequence of LGS (SEQ ID NO:345), and a CDR-L3 comprising the amino acid sequence of MQSLQTFT (SEQ ID NO:346);
• (b) a second epitope bin comprising epitopes of one or more of anti-Ara h 2 antibodies P31, T4, T5, S4, 14FU2P1 D6, 15FU1P3A6, 13FU1P2B10, and 27FU1P3A10, wherein P31 comprises the following CDRs:
• a CDR-H1 comprising the amino acid sequence of GDPFTSYY (SEQ ID NO:301), a CDR-H2 comprising the amino acid sequence of IFTTGST (SEQ ID NO:302), a CDR-H3 comprising the amino acid sequence of ARVRRYCSGGRCYPYFYMDV (SEQ ID NO:303), a CDR-L1 comprising the amino acid sequence of ESISSW (SEQ ID NO:304), a CDR-L2 comprising the amino acid sequence of EAS (SEQ ID NO:305), and a CDR-L3 comprising the amino acid sequence of QHYNSDSLT (SEQ ID NO:306);
• (c) a third epitope bin comprising an epitope of anti-Ara h 2 antibody S1, 27FU1P3A4, 6BU4P2B1, and 89BU7P1B10, wherein S1 comprises the following CDRs:
• a CDR-H1 comprising the amino acid sequence of GFSFSDSY (SEQ ID NO:381), a CDR-H2 comprising the amino acid sequence of ISGSGEII (SEQ ID NO:382), a CDR-H3 comprising the amino acid sequence of ARPSDYFETSEELD (SEQ ID NO:383), a CDR-L1 comprising the amino acid sequence of QSISTY (SEQ ID NO:384), a CDR-L2 comprising the amino acid sequence of AAS (SEQ ID NO:385), and a CDR-L3 comprising the amino acid sequence of HQSYSAPRT (SEQ ID NO:386);
• and, optionally,
• (d) a fourth epitope bin comprising epitopes of one or more of anti-Ara h 2 antibodies P7, P6, 111BU7P1A12, 111BU7P1D2, 111BU7P1D5, 24BU7P1D3, and 24BU7P1B1, wherein P7 comprises the following CDRs:
• a CDR-H1 comprising the amino acid sequence of GFTFTRYA (SEQ ID NO:41), a CDR-H2 comprising the amino acid sequence of ISHDGGTK (SEQ ID NO:42), a CDR-H3 comprising the amino acid sequence of AKTCSSPSCYDTAYYFDY (SEQ ID NO:43), a CDR-L1 comprising the amino acid sequence of QSLGNY (SEQ ID NO:44), a CDR-L2 comprising the amino acid sequence of DAS (SEQ ID NO:45), and a CDR-L3 comprising the amino acid sequence of QQRSQFMWT (SEQ ID NO:46).